Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall ...

Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S ...

Anyone seeking to report adverse effects should contact Bausch + Lomb at 800-338-2020, option 1, or submit a report to the FDA’s MedWatch program (800-332-1088 to request a form).

Young Boys' Jordan Siebatcheu, left, scores his side's opening goal against Leverkusen's goalkeeper Niklas Lomb during the Europa League round of 32, 2nd leg soccer match between Bayer 04 ...

Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.

Bausch + Lomb is down 34.4% since the beginning of the year, and at $11.81 per share, it is trading 43.6% below its 52-week high of $20.93 from October 2024. Investors who bought $1,000 worth of ...

Bausch + Lomb beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $1.28 billion, up 9.1% year on year. It was a mixed quarter for the company, with a decent beat of ...

Bausch + Lomb said on Friday it would acquire several Novartis eye-care products for $1.75 billion as their market grows, sending the company's shares up over 8% in early trading.

Meanwhile, Bausch + Lomb is estimated to provide $4.7 billion in revenue and $860 million in EBITDA (earnings before interest, taxes, depreciation, and amortization) this year.

Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S ...